bluuebunny/crossref_metadata_2025_split huggingface dataset:
Personality is associated with dominance in a social feeding context in the great tit
Authors: Bibi Nehafta , Wei Yusheng , Xu Hongwei , Liang Jingnan , Hussain Ijaz , Ahmad Munawar Saleem , Wang Haitao 
Published: October 2019

Abstract
Despite the growing interest in consistent individual differences in behaviour (animal personality), the influence of social context on different behavioural types remains poorly understood. The suite of correlated behaviours within and across contexts is called behavioural syndromes. Most personality studies have investigated consistent individual behavioural types and their consequences in a asocial context, however few studies have considered the influence of social context on individual behaviour. In addition, the evolutionary and ecological consequences of personality differences in social context remain unknown. In the present study, we confirm individual personality in Great tits (Parus major) using room exploration and neophobia tests. As a result of these two tests, repeatability and correlational structure of two personality traits were investigated. Additionally we assessed the extent to which personality influences dominance in a social feeding context.
Great tits remained consistent in their personality traits (exploration and neophobia). Individuals who explored a novel environment faster also approached a novel object faster, while those who spent more time exploring a novel environment were also slower to approach a novel object. In a social feeding context personality was linked to dominance: with proactive individuals being more likely to be dominant. Our result provides evidence of the importance of social context in a wild population of birds and may have fitness consequence, both for focal individuals and their conspecifics.
Remembering Savva Ivanovich Mamontov
Authors: Vasnetsov Viktor 
Published: October 2019

Abstract
At the memorial service held for Savva Mamontov after his death in 1918, Viktor Vasnetsov delivered his reminiscences by way of a eulogy. He describes his relationship with the impresario, some key moments in the history of the Abramtsevo circle and his own artistic life. In so doing, Vasnetsov conveys the deep affection held by artists in the circle for Mamontov, and hints at some of the reasons why his role was so critical and influential in coaxing the group towards their many artistic successes.
“Dreaming of Russia”
Authors: Davydova Olga 
Published: October 2019

Abstract
The National-Romantic trend in Russian Art Nouveau is characterized by a lyrical approach to the past, including imagery from folklore. This tendency is also identifiable within the global development of Art Nouveau, each country expressing its national identity in highly characteristic forms in design and architecture. Art Nouveau coincided with the zenith of Symbolism and, therefore, transmitted both its universal ideas and the unique creative psychology of the individual artist, who often based personal quest upon local traditions and innate cultural memory. This article analyzes the poetics of this style in Russia. The lyrical and mythological approach towards artistic images, influencing design, form, and meaning, is studied through an examination of the works of artists close to the Abramtsevo circle and the innovative experiments of the World of Art group (1898-1904).
“Parallel” Muftiates as the “Third Force” among Spiritual Administrations of Muslims in Russia
Authors: Bekkin Renat 
Published: October 2019

Abstract
Throughout 230-year long history, from Russian Empire, through Soviet Union to present day Russia the institution of muftiate has continuously served as an instrument of state religious policy in relation to Muslims. Guided by various considerations, the authorities have kept the institution itself but did not allow individual muftiates to create a united all-Russian Muslim centre. The article discusses such a phenomenon of 2010s as “parallel” muftiates, designed to become an alternative, “third force” to the existing federal muftiates. The article hypothesizes that one of the main tasks of “parallel” muftiates is to prevent federal muftiates from uniting.
Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus Treated by Autologous Hematopoietic Stem Cell Transplantation.
Authors: Statkute Laisvyde , Burt Richard K. , Oyama Yu , Verda Larissa , Krosnjar Nela , Traynor Ann E. 
Published: October 2019

Abstract
The association of antiphospholipid antibodies (APLA) with either vascular thrombosis or fetal morbidity is known as the antiphospholipid syndrome (APS). Since systemic lupus erythematosus (SLE) is frequently associated with APS, we analyzed 44 patients with severe and refractory SLE involved in a larger study of autologous hematopoietic stem cell transplantation (HSCT) utilizing cyclophosphamide and antithymocyte globulin (ATG) conditioning to determine the efficacy of this treatment in eliminating APLA and preventing recurrent thrombi. The prevalence of SLE-related APS in our patient population was 63% (45% met Sapporo criteria for definite APS, and 18% had history of APLA positivity with associated clinical APS features). Nineteen patients with APS had lupus anticoagulant (LA) and/or high titers of anticardiolipin antibodies (ACLA) at the entry into study. Ten patients were positive for LA. Fourteen patients showed elevated titers of ACLA, IgG and/or IgM. When followed for up to 30 months after autologous HSCT, 70% of initially LA-positive patients became and remained negative for anticoagulant. 79% demonstrated normalization of ACLA titers during maximum of 28 months follow-up. 64% of patients refractory to chronic anticoagulation regimen were able to discontinue from anticoagulation therapy at average of 6 months post-transplant and remained thrombotic events-free and in complete SLE remission for up to 78 months after HSCT. There was no treatment-related mortality or severe adverse events, including stem cell engrafment-related hematological complications or overhelming bacterial, fungal or viral infection, in any of the 28 SLE-related APS patient. Autologous hematopoietic stem cell transplantation may be performed safely and appears to be effective therapy for eliminating SLE-related APLA and preventing further thrombotic events.
PKC412, a FLT3 Inhibitor, Effectively Induces Apoptosis of Leukemia Cells with 11q23 Translocation Particularly Having D835 Mutation.
Authors: Takahashi Kazuya , Goi Kumiko , Furuichi Yoshiyuki , Inukai Takeshi , Sugita Kanji , Nakazawa Shinpei 
Published: October 2019

Abstract
About 30% cases of acute myeloid leukemia (AML) show FLT3 mutations such as internal tandem duplications within the juxtamembrane domain and point mutations within the kinase domain (D835 et al), which result in constitutive activation of FLT3 kinase activity. Although it was recently shown that acute lymphoblastic leukemia (ALL) with 11q23 translocation, often found in infantile leukemia with very poor prognosis, express FLT3 at high levels, few studies have been performed regarding the biological implication of FLT3 in leukemia with 11q23 translocation. We recently found that 2 of 6 cell lines with 11q23 translocation had D835 mutation in FLT3 (KOCL-33 with 11; 19 translocation and B-precursor phenotype, and KOCL-48 with 4; 11 translocation and monocytoid phenotype). In the present study, we evaluated the in vitro inhibitory effects of PKC412 (a kinase inhibitor of FLT3) using leukemic cell lines with or without D835 mutation. 3H-thymidine uptakes were inhibited by PKC412 at 50–200 nM very markedly in two 11q23-cell lines with D835 mutation (>90% inhibition), moderately (50–80% inhibition) in 11q23-cell lines without FLT3 mutation (n=5), but only modestly (<50% inhibition) in other B-precursor cell lines without FLT3 mutation (n=5). Two 11q23-cell lines with D835 mutation were effectively induced into apoptosis by PKC412, which was preceded by a prompt disappearance of constitutive phosphorylation of STAT5 before PKC412 treatment. The RNase protection assay revealed a decrease in mRNA of Bfl-1 which is known to be up-regulated by the NFkB activity, but showed no changes in mRNA of apoptosis-related molecules such as Bcl-2, Bcl-xl, Bad, Fas, FasL, and TRAIL. These results suggest that PKC412 is a potentially useful agent for the treatment of leukemia with 11q23 translocation, particularly having FLT3 mutation.
The Expression of Human Leukocyte Formin Protein, a New Protein That Associates with AKT, Is Correlated with the Expression of ZAP-70 in CLL.
Authors: Favaro Patricia M.B. , Medina Samuel S. , Traina Fabiola , Oliveira Gislaine B. , Metze Irene L. , Costa Fernando F. , Saad Sara T.O. 
Published: October 2019

Abstract
Recently, we have cloned a new human gene (GenBank Accession No. AY278319), belonging to the formin family. This new gene, called for us human leukocyte formin, presents the common domains found in formin-related proteins: FH1, FH2 and FH3 domains. Western Blotting analysis has demonstrated that the protein encoded by this gene is overexpressed in lymphoid malignancies and cancer cell lines. Based on this pattern of expression, our objective was to investigate the expression of human leukocyte formin protein, by Western blotting analysis, in mononuclear cells from chronic lymphocytic leukemia (CLL) patients, isolated on a Ficoll-Hypaque gradient. We studied 18 CLL patients with median age of 65 y.o. (range, 45 to 86) out of treatment for at least three months (Rai 0 n=8; Rai 1 n=6; Rai 2 n=1; Rai3 n=1; Rai 4 n=2). As normal control we used 6 blood donors. Our data showed an overexpression of the human leukocyte formin in the CLL group when compared with the control group (p= 0.0354), as well as a positive correlation of this protein and ZAP-70 in the CLL group (Spearman test, p= 0.0107). The expression of ZAP-70 has been associated with rapid progression and poor survival and can be used as a prognostic marker. Previously we had described that human leukocyte formin protein associates with Akt, a critical survival regulator in many different cell types. The association was observed in a protein extract of Jurkat cell line and in peripheral blood leukocytes from CLL patients. In an attempt to confirm the association between Akt and human leukocyte formin, we performed cotransfections in 293 cells using an expression vector pEGFP containing FH2 or FH3 domains, and an expression vector of pCMV-HA containing the full length of Akt. The results showed that both FH2 and FH3 domains are involved in the association with Akt. The correlation of human leukocyte formin and ZAP-70 expression, and the association of human leukocyte formin protein with Akt suggest that this new protein may be involved in the signaling pathway of leukemia cell survival and is possibly a new prognostic marker.
PCR-Based Liposomal Amphotericin B Treatment Following Allogeneic Stem Cell Transplantation Is a Safe Treatment Strategy: Preliminary Results of a Prospective Study.
Authors: Hebart Holger , Klingspor L. , Klingebiehl Thomas , Loeffler Juergen , Tollemar J. , Ljungman Per , Wandt Hannes , Dornbusch H.J. , Schumacher Ulrike , Meisner Christoph , Engel C. , Kanz Lothar , Ringden Ole , Einsele Hermann 
Published: October 2019

Abstract
A prospective randomized multi-center trial was initiated comparing PCR-based preemptive and empirical antifungal therapy with AmBisome in patients after allogeneic stem cell transplantation.
A total of 408 patients were randomized at the time of transplant to the antifungal treatment strategy. PCR screening was planned twice weekly during stay in hospital and once weekly after discharge until day 100 post-transplantation. Antifungal prophylaxis consisted of up to 200 mg fluconazole/day. Antifungal therapy was initiated in the PCR group in PCR+ patients with signs of infection and patients with 2 consecutive positive PCR results, and in the empirical treatment group (group B) after 120 hours of febrile neutropenia not responding to broad-spectrum antibacterial therapy. Antifungal treatment consisted of AmBisome at 3 mg/kg for 3 days (loading dose) followed by AmBisome at 1 mg/kg in clinically stable patients, AmBisome at 3 mg/kg was continued in clinically unstable patients. Treatment was stopped according to pre-defined study rules.
The two arms were well balanced with regard to age, gender, donor type, underlying disease and stage, and conditioning regimens applied. Out of 403 evaluable patients 196 were randomized to group A and 207 to group B. AmBisome therapy was initiated in 109 patients in group A and in 76 patients in group B (P<0.05). Eleven patients in group A and 16 patients in group B developed proven invasive fungal infections (IFI), overall mortality at 100 and 180 days was not different. Survival curves demonstrated a lower mortality until day 30 post-transplantation for patients receiving PCR-based antifungal therapy with AmBisome (deaths in group A, n=4; group B, n=13; P=0.03). During this early time period when regular PCR-screening was performed, only 1 patient in group A (candidiasis) and 5 patients in group B (invasive aspergillosis, n=1; candidiasis, n=4) succumbed to IFI (P=0.1).
This study prospectively compared PCR-based versus empirical antifungal therapy with AmBisome after allogeneic SCT. A reduction in early mortality and a trend for a lower rate of proven invasive fungal infections was documented until day 30 post-transplantation indicating that close fungal PCR monitoring allows to stratify patients at high risk for the subsequent development of invasive fungal infections. Survival at day 100 and 180 post-transplantation was not different.
Effect of Polymorphisms in Folate Related Genes on Side Effects of High Dose MTX Treatment in Childhood Acute Lymphoblastic Leukemia.
Authors: Tissing Wim , Huang Lisha , de Jonge Robert , Pieters Rob 
Published: October 2019

Abstract
Introduction. High dose (2 – 3 g/m2) methotrexate (MTX, an anti-folate) is used in the treatment of pediatric acute lymphoblastic leukemia (ALL) with side effects in a considerable number of children. We studied the prevalence of MTX related side effects and a possible relation with common polymorphisms in folate metabolism related genes in the treatment of childhood ALL.
Methods. In this retrospective study, DNA was isolated from leukemic samples of 81 children with ALL. High risk (HR) ALL patients were treated with 4 courses of 3 g/m2, non-high risk (NHR) patients with 3 times 2g/m2. The following effects were monitored: serum MTX levels, transfusion need, liver toxicity, skin toxicity and hematological toxicity. Common gene mutations in methylenetetrahydrofolate reductase (MTHFR 677C>T and MTHFR 1298A>C), methionine synthase (MS 2756A>G), methionine synthase reductase (MTRR 66A>G), serine hydroxymethyl transferase (SHMT 1420C>T), methylenetetrahydrofolate dehydrogenase (MTHFD1 1958G>A), thymidylate synthase (TS 2R3R) and reduced folate carrier (RFC 80G>A) were detected by PCR-RFLP.
Results. 57% of the patients had prolonged increased serum levels of MTX in at least 1 course. 59% patients had the MTX courses at the scheduled time, 35% had one course postponed and 6% 2 courses. Mucositis was observed in 22% patients after 1 out of 3 courses, 19% after 2 and 20% after 3 courses. 28% patients had 1 transfusion, 6% had 2 and 1% had 3 transfusions during the MTX courses. Transaminases were elevated 2 times above the normal upper level in 25% of the patients. Skin rash was observed in 32% patients.
Using Mann Whitney analysis we found a significant relation between polymorphisms of the MTHFR 1298A>C and for the MTRR 66A>G genes and side effects. The MTHFR 1298A>C polymorphism was related to less transfusions (p<0.05). Recovery of WBC count in HR ALL patients tended to be slower in patients with a MTHFR 1298AA genotype (P=0.053). HR patients with a MTRR 66AG genotype had a slower recovery of platelet count (p=0.004)
Conclusion. Common polymorphisms in the MTHFR (677C>T), MS, SHMT, TS, RFC, and MTHFD1 genes are not related to the occurrence of side effects of MTX treatment in childhood ALL. Polymorphisms in the MTHFR (1298A>C) and MTRR (66A>G) gene are related to hematological toxicity.
B-Aggressive Lymphoma Gene (BAL) Is a Risk-Related, γIFN-Inducible Gene That Is Expressed in Primary Diffuse Large B-Cell Lymphomas with a Brisk Host Inflammatory Response.
Authors: Juszczynski Przemyslaw , Kutok Jeffery L. , Aguiar Ricardo C.T. , Mitra Joydeep , Shipp Margaret A. 
Published: October 2019

Abstract
Although diffuse large B-cell lymphoma (DLBCL) is potentially curable with current therapy, a significant number of DLBCL patients still die of their disease. In a broad-based screen for genes and pathways associated with poor DLBCL outcome, we previously identified a novel risk-related gene, termed BAL (B-aggressive lymphoma). Thereafter, we cloned and characterized a major BAL partner protein, BBAP (B-aggressive lymphoma and BAL binding partner), described the nuclear trafficking patterns of both proteins and demonstrated that BAL functions as a modulator of transcription. In the current study, we characterized BAL expression in normal tonsil and primary DLBCLs and defined BAL regulation and potential functions in both cell types. Immunohistochemical staining of normal tonsil revealed that BAL was expressed by small numbers of germinal center (GC) cells and interfollicular cells with the morphologic features of centroblasts (with the GC) and immunoblasts (within the interfollicular areas). In primary DLBCLs, BAL was expressed by the malignant B cells. To gain insights regarding the regulation of BAL and BBAP expression in DLBCLs, we analyzed a series of 176 primary tumor biopsies transcriptionally profiled an U133A/B Affymetrix microarrays. BAL/BBAP high-expressing DLBCLs had evidence of a brisk host immune response, including increased expression of T/NK-cell receptor and activation pathway components, complement cascade members, macrophage/dendritic cells markers and γIFN-induced transcripts, raising the possibility that BAL was induced by γIFN. Consistent with this hypothesis, γIFN treatment of DLBCL cell lines with low basal levels of BAL markedly increased BAL expression. In silico analysis revealed that the BAL and BBAP genes are located in 3q21 in head-to-head orientation and share the same CpG-related promoter. This shared promoter contains a conserved γIFN-responsive module composed of IRF and STAT binding elements. The BAL/BBAP bidirectional promoter was cloned into a pGL3 luciferase promoterless reporter vector and found to increase luciferase activity > 20-fold following γIFN stimulation. To gain further insights into regulation of BAL transcription, mutant versions of BAL promoter were generated and cloned. Luciferase assays demonstrated that the IRF binding site was necessary for γIFN-induced BAL transcription, whereas the STAT1 binding site had an accessory role. Taken together, these results demonstrate that BAL and BBAP genes are transcriptionally activated by γIFN in DLBCLs with features of a brisk host immune response including γIFN signaling. Preliminary studies suggest that BAL limits the efficacy of the observed host inflammatory response.
Response of the Thrombocytopenia Associated with Dengue Hemorrhagic Fever to WinRho® SDF: A Case Series.
Authors: De Castro Reynaldo Angelo C. , Dixit Jitendra R. , Genereux Maurice G. 
Published: October 2019

Abstract
Background: Dengue Fever (DF) illness caused by any of the four serotypes of dengue virus (flavivirus) is currently the most important mosquito borne viral disease in the tropical areas of the world. Dengue hemorrhagic fever (DHF) is a potentially lethal complication of DF.
An estimated 500,000 cases of DHF require hospitalisation each year, of which a very large proportion are children. The case fatality rate varies from 1 to 5% and can exceed 20% without proper treatment.
Thrombocytopenia in DHF: Thrombocytopenia is a constant finding in DHF/Dengue Shock Syndrome (DSS). The platelet count usually decreases to below 100,000 /mm3, 1–2 days before defervescence and remains low for 3–5 days in most cases. The cause of thrombocytopenia is not clearly understood and may be due to decreased platelet production, increased peripheral destruction, or both.
Method: We report a case series in 19 patients from different hospitals around Manila. Pediatric patients who fulfilled the WHO criteria of DHF: high fever, bleeding, positive tourniquet test, moderate to severe thrombocytopenia (<100,000 /mm3) and hemoconcentration (Hematocrit increase> 20%) were included in the case study after voluntary, written, informed consent was provided by parent or proxy.
All subjects meeting the eligibility criteria received a single dose of WinRho® SDF which was administered at a dose of 20 μg/kg over 15 minutes. WinRho® SDF was administered when the platelet count dropped below 100,000 /mm3. Platelet counts were measured every 24 hours.
Findings: All 19 patients showed an increase in the platelet count after administration of WinRho® SDF. Figure 1 summarizes the average platelet count for the 19 patients before and after treatment with WinRho® SDF. Day 0 indicates the date of administration of WinRho® SDF. 48 hours after administration of WinRho® SDF, the platelet count returned to normal (> 150,000) in all patients. All 19 patients also showed clinical improvement and were discharged from hospital within 96 hours. There were no serious adverse events observed in any patient.
Fig 1: Change in average platelet count before and after treatment with WinRho® SDF. Fig 1:. Change in average platelet count before and after treatment with WinRho® SDF.
Conclusion:
All 19 patients showed a rapid increase in the platelet count after administration of WinRho® SDF. 48 hours after administration of WinRho® SDF, the platelet count returned to normal in all patients. All the patients showed clinical improvement and were discharged from hospital within 96 hours.
WinRho® SDF is currently licensed to treat immune thrombocytopenia purpura (ITP) in pediatric or adult patients. Unlike other disease states which may produce ITP, the thrombocytopenia associated with DF has an acute onset and a high mortality rate if untreated. The response observed in these patients demonstrates that the thrombocytopenia associated with DF responds rapidly to treatment with WinRho® SDF.